Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh (JNJB34) Price & Analysis

Q: Is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh overvalued?

According to Wall Street analysts Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh?

Currently, no hedge funds are holding shares in BR:JNJB34

― Followers

JNJB34 Stock Chart & Stats

R$91.50

-R$0.60(-0.65%)

Sep 18, 2026

―

Day’s Range― - ―

52-Week RangeR$61.72 - R$96.19

Previous CloseN/A

VolumeN/A

Average Volume (3M)8.60K

Market Cap

R$3.35T

Enterprise ValueR$3.34M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)30700.0

Beta-0.16

Next Earnings

Oct 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding36,152,094,000

10 Day Avg. Volume6,438

30 Day Avg. Volume8,599

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh News

U.S. weighs allowing most pharma licensing deals with China, Reuters says

The U.S. is working on rules for pharmaceutical companies investing in China that would likely preserve their ability...

1d ago

AZN

BMY

PepsiCo names Joaquin Duato to Board of Directors

PepsiCo (PEP) announced its Board of Directors has elected Joaquin Duato as an independent member of the Board....

2d ago

JNJ

PEP

Nanobiotix assumed with a Buy at Guggenheim

Guggenheim assumed coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target. The firm’s investment thesis...

5d ago

JNJ

NBTX

Johnson & Johnson announces new results from COPERNICUS study

Johnson & Johnson announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous Rybrevant Faspro plus...

5d ago

JNJ

Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint

The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint....

5d ago

JNJ

CTNM

Johnson & Johnson reports PAPILLON study meets primary endpoint

Johnson & Johnson announced results from the final overall survival, or OS, analysis of the Phase 3 PAPILLON...

6d ago

JNJ

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

Nanobiotix (NBTX) announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase...

6d ago

JNJ

NBTX

Apollo Global in talks to buy J&J’s orthopedics unit, Bloomberg reports

Apollo Global Management (APO) is in talks to acquire the Johnson & Johnson (JNJ) orthopedics unit that the...

8d ago

APO

JNJ

Apollo Global in discussions to buy JNJ’s orthopedics unit, Bloomberg reports

18:28 EDT Apollo Global (APO) in discussions to buy JNJ‘s orthopedics unit, Bloomberg reports Published first on TheFly...

8d ago

APO

JNJ

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring...

10d ago

JNJ

J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Nedelcovych Buy Rating

In a report released yesterday, Michael Nedelcovych from TD Cowen maintained a Buy rating on Johnson & Johnson,...

5d ago

JNJ

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on Johnson & Johnson, retaining the price target...

2M ago

JNJ

Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Johnson & Johnson, retaining the price target...

2M ago

JNJ

Johnson & Johnson: Talc Settlement Progress Removes Major Overhang; Buy Rating Reiterated with Unchanged $282 Price Target

Johnson & Johnson, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider...

2M ago

JNJ

JNJB34 FAQ

What was Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price range in the past 12 months?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh lowest stock price was R$61.72 and its highest was R$96.19 in the past 12 months.

What is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s market cap?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s market cap is R$3.35T.

When is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s upcoming earnings report date?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s upcoming earnings report date is Oct 13, 2026 which is in 23 days.

How were Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s earnings last quarter?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh released its earnings results on Jul 15, 2026. The company reported R$0.001 earnings per share for the quarter.

Is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh overvalued?

According to Wall Street analysts Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh pay dividends?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh does not currently pay dividends.

What is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s EPS estimate?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh have?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh has 36,152,094,000 shares outstanding.

What happened to Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price movement after its last earnings report?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh reported an EPS of R$0.001 in its last earnings report. Following the earnings report the stock price went down -1.778%.

Which hedge fund is a major shareholder of Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh?

Currently, no hedge funds are holding shares in BR:JNJB34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology